Last reviewed · How we verify
NCT04172272: TAP
The Influence of TAP Block in the Control of Postoperative Pain After Laparotomy for Gynecological Procedures
NA trial testing Systemic multimodal analgesia administered intravenously in Leiomyoma in 75 participants. Status unknown.
24 September 2020
Quick facts
| Lead sponsor | General Hospital Pula |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 75 |
| Start date | 24 September 2019 |
| Primary completion | 24 September 2020 |
| Estimated completion | 31 December 2021 |
| Sites | 2 locations across Croatia |
Drugs / interventions tested
- Systemic multimodal analgesia administered intravenously — full drug profile →
- Transversus abdominis plane block (TAP block)
- Combined transversus abdominis plane block (TAP block) with systemic multimodal analgesia administered intravenously
Conditions studied
- Leiomyoma — all drugs for Leiomyoma →
- Pelvic Organ Prolapse — all drugs for Pelvic Organ Prolapse →
- Abnormal Uterine Bleeding — all drugs for Abnormal Uterine Bleeding →
- Chronic Pain — all drugs for Chronic Pain →
Sponsor
General Hospital Pula
Who can join
18 and older, female only, with Leiomyoma or Pelvic Organ Prolapse. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates the influence of the transversus abdominis plane block on the intensity of postoperative pain and the concentration of proinflammatory and pain factors after hysterectomy by laparotomy. The patients will be randomized in three groups.In the first group, patients will receive intravenous, systemic, multimodal analgesia.In the second group there will be patients in who will be given the TAP block. The TAP block will be given postoperatively before waking. It will be given bilaterally in the before mentioned anatomic region (the so-called lateral TAP block). In the third group there will be patients who will be treated with TAP block in addition to systemic, mutimodal analgesia. The research will be based on completing a questionnaire (VAS scale and QoR questionnaire) and taking peripheral blood out. We expect that the concentration of proinflammatory and pain factors in patients treated with a TAP block will be lower and the quality of recovery will be better than that of patients receiving standard analgesic therapy (systemic multimodal analgesia).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04172272
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Leiomyoma
Currently open trials in the same condition.
- NCT06143631 — Prescription of Letrozole for Uterine Myoma · Phase 4 · recruiting
- NCT06135870 — Role of Senescent Cells in Uterine Fibroid Pathogenesis (SOUL Study) · recruiting
- NCT03400826 — Effects of Simvastatin on Uterine Leiomyoma Size · Phase 2 · recruiting
Other General Hospital Pula trials
Trials by the same sponsor.
- NCT04607018 — Effect PMA-Zeolite on the Mineral Metabolism and Blood Parameters (MMBP Study) · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04172272 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by General Hospital Pula
- Last refreshed: 21 November 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04172272.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing